Peptide PEGylation: The Next Generation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peptide PEGylation: The Next Generation
Linking peptides to polyethylene glycol, or PEGylation, has helped improve pharmaceutical therapeutics in several ways. A wave of new techniques is now ushering in further advances.


Pharmaceutical Technology
Volume 35, pp. a26-s28

Effective PEGylation

The solutions presented herein provide many options to help one decide how to PEGylate a given peptide most effectively. However, there are three factors that must be taken into account because they can affect the efficiency of PEGylation: the number of chains attached to a peptide; the molecular weight and structure of the PEG chains; and the attachment site of PEG.

In recent work (11), a synthetic peptide inhibiting the binding of human neonatal Fc receptor to immunoglobulin was PEGylated in a number of different ways. In vitro and in vivo activity was then compared to determine which method was the most effective. Three different amino acids were either replaced with lysine, or a C-terminal amine was generated, or a linker amine was generated. The PEGylated peptides were more active in mice compared with the nonPEGylated version, but only when linked through a specific linker. The linear version was more active compared with the branched version. Because technology now exists to make different versions, a few should be tested for each specific peptide.

As PEGylation becomes more well used, such comparative studies may help optimize future PEGylation strategies. Additionally, as more peptides become drug candidates, testing different ways of linking them to PEG may become a routine part of fine-tuning them for their final clinical manifestations.

Baosheng Liu is vice-president of research and manufacturing at the American Peptide Company, 777 E. Evelyn Avenue, Sunnyvale, CA 94086.

References

1. G. Pasut and F.M. Veronese, Drugs of Today 45 (9), 687–695 (2009).

2. H.F. Gaertner and R.E. Offord, Bioconjug. Chem. 7 (1), 38–44 (1996).

3. M.J. Roberts, M.D. Bentley, and J.M. Harris, Advanced Drug Delivery Reviews 54 (4), 459–476 (2002).

4. V.M. Veronese, Biomaterials 22 (5), 405–417 (2001).

5. A.D. Sezer and A.F. Yagci, Acta. Pharmaceutica. Sciencia 52(4), 376–388 (2010).

6. C.P. Chen et al., Bioconjug. Chem. 18 (2), 371–378 (2007).

7. F.F. Schumacher, Bioconjug. Chem. 22 (2), 132–136 (2011).

8. G.M. Cox et al., Endocrinology 148 (4), 1590–1597 (2007).

9. M.S. Rosendahl, Bioconjug. Chem. 16 (1), 200–207 (2005).

10. D.H. Doherty, Bioconjug. Chem. 16 (5), 1291–1298 (2005).

11. A.R. Mezo et al., Bioorg. Med. Chem. 16 (12), 6394–405 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here